LDS/Medical Tests/Paroxetine, Serum

Paroxetine, Serum

Paroxetine is one of the selective serotonin reuptake inhibitors typically known as SSRIs, and belong to the class of drugs known as antidepressants. However, Fluvoxamine has only been approved by the FDA for treatment of obsessive-compulsive disorder. Regardless, as a class SSRIs have become the first-line pharmaceutical treatment of depression in the United States and treat depression by increasing serotonergic activity. Other clinical uses of antidepressants are for disorders or clinical conditions such as obsessive-compulsive disorder, chronic pain, eating disorders, anxiety or panic disorders, peptic ulcer disease or childhood enuresis. The SSRIs typically do not elicit the anticholinergic side effects of the TCAs, are easier to tolerate, are not as toxic, and are safer for the patient. As occurs with most drugs, there are some side effects of SSRI use including anxiety, sleep disturbances, sexual dysfunction, and insomnia.

The SSRIs are lipophilic, have large volumes of distribution, well absorbed in the gastrointestinal tract, and reach peak plasma concentrations within one to eight hours. Most SSRIs are metabolized by the cytochrome P450 system and many of the metabolites are pharmacologically active. Paroxetine is not metabolized appreciably to a pharmacologically active compound. The half-lives of these particular drugs are quite variable. The half-life of paroxetine is between 3-65 hours. SSRI plasma concentrations are not routinely measured because they have not been show to correlate with clinical response.

The effects associated with paroxetine abuse include hallucinations, tachycardia, seizures, nausea, vomiting, tremors, and coma when taken to excess.

In conclusion, SSRIs, including paroxetine are frequently prescribed and therefore encountered drugs.

  • Drug abuse evaluation
  • Toxicity assessment
  • Patient Compliance
  • Potential identification of rapid metabolizers
A qualitative positive result from an immunoassay (IA) type test indicates only the presence of SSRIs and does not necessarily correlate with the extent of physiological and psychological effects. Any positive result should be confirmed by a non-immunological method such as GC/MS or LC/MS.

Therapeutic concentration in blood: variable
Toxic concentration: variable
Fatal concentration: variable

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration is preferred for pharmacokinetic analyses.

Cut-Off Ranges
Cut-off values are generally used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection whether it is a qualitative method such as IA, or a quantitative method such as GC/MS or LC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.

Primarily Immunoassay (IA), Gas Chromatography/Mass Spectroscopy (GC/MS), or Liquid Chromatography/Mass Spectroscopy (LC/MS) techniques are used in the laboratory analysis of SSRIs. The main method used for quantification is LC/MS. This particular method can be used to detect SSRIs such as paroxetine. Paroxetine can be separated from biological specimens by liquid-liquid extraction or by solid-phase extraction. When analyzing urine specimens, a hydrolysis step may be required to free the parent drug and metabolites from glucuronide conjugates. Enzymatic hydrolysis is generally preferred over acid hydrolysis.

Serum (SST) or plasma (EDTA).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
Pharmacogenetic testing, such as genotyping *CYP3A4, CYP2D6, CYP2C19,* which are primarily responsible for metabolism of SSRIs, may be useful. Therefore, genotyping of these variants could guide drug and dose selection. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Antidepressant DEA Drug Fact Sheet.
  • Levine, Barry (Ed). Therapeutic Drugs II: Antidepressants. In: Principles of Forensic Toxicology, 4th Ed. Washington DC: AACC Press; 2013: 403-420.
  • Balant-Georgia AE, Balant LP. Milestones in clinical pharmacology. Therapeutic drug monitoring of antidepressants. Clin Ther. 1992;14(4):612-4.
  • Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Littleton, MA: PSG Publishing Co.; 1987.
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications; 2002.
  • Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7):169-79.
  • Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds). Goodman and Gilman’s the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill Co.; 1996
  • Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology. 1989;11(4):7-20.
  • Zherdev VP, Caccia S, Garattini S, Ekonomov AL. Species differences in phenazepam kinetics and metabolism. Euro J Drug Metab Pharm. 1982;7:191-6